{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:55:11Z","timestamp":1782345311940,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11883-017-0683-9","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:51:22Z","timestamp":1507683082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Statin Prescribing in the Elderly: Special Considerations"],"prefix":"10.1007","volume":"19","author":[{"given":"M.","family":"Leya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"issue":"21","key":"683_CR1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2014.08.040","volume":"64","author":"NK Wenger","year":"2014","unstructured":"Wenger NK. Alice in lipidland. J Am Coll Cardiol. 2014;64(21):2193\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"683_CR2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/01.CIR.0000013074.73995.6C","volume":"105","author":"MA William","year":"2002","unstructured":"William MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >\u00a0or =75 years of age): an American Heart Association scientific statement from The Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2002;105(14):1735\u201343.","journal-title":"Circulation"},{"issue":"15","key":"683_CR3","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.291.15.1864","volume":"291","author":"DT Ko","year":"2004","unstructured":"Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864\u201370.","journal-title":"JAMA"},{"issue":"13","key":"683_CR4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2010.01.013","volume":"55","author":"K Gransbo","year":"2010","unstructured":"Gransbo K, Melander O, Wallentin L. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. JACC. 2010;55(13):1363\u20139.","journal-title":"JACC."},{"issue":"25","key":"683_CR5","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.jacc.2017.05.011","volume":"69","author":"B Gaye","year":"2007","unstructured":"Gaye B, Canonico M, Perier M, Samieri C, Berr C, Dartigues J, et al. Ideal cardiovascular health, mortality, and vascular events in elderly subjects. JACC. 2007;69(25):3015\u201326.","journal-title":"JACC."},{"issue":"25 Pt B","key":"683_CR6","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"\u2022\u2022 Stone NJ, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. JACC. 2014;63(25 Pt B):2889\u2013934. The latest guidelines from the ACC\/AHA on statin prescribing, with special consideration of evidence-based practices doe prescribing in individuals over 65 years. Statins for secondary prevention are recommended for patients up to 85 years old, and for primary prevention with a risk discussion for patients 65 to 75 years old","journal-title":"JACC"},{"issue":"19","key":"683_CR7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","volume":"316","author":"US Preventive Services Task Force","year":"2016","unstructured":"\u2022\u2022 US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults. US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997\u20132007. The current recommendations from the USPSTF for prescribing statins in those 40 to 75 years of age based on their degree of cardiovascular risk recognizes the current limited evidence for prescribing statins for primary prevention in those older than 75 years of age","journal-title":"JAMA"},{"issue":"1","key":"683_CR8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjopharm.2007.03.008","volume":"5","author":"R Ali","year":"2007","unstructured":"Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geri Pharmacotherapy. 2007;5(1):52\u201363.","journal-title":"Am J Geri Pharmacotherapy"},{"issue":"7","key":"683_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.1995.03530070037026","volume":"274","author":"MC Corti","year":"1995","unstructured":"Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274(7):539\u201344.","journal-title":"JAMA"},{"issue":"22","key":"683_CR10","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","volume":"62","author":"G Savarese","year":"2013","unstructured":"Savarese G, Gotta AM, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. JACC. 2013;62(22):2090\u20139.","journal-title":"JACC"},{"issue":"10","key":"683_CR11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.amjcard.2006.06.039","volume":"98","author":"JG Robinson","year":"2006","unstructured":"Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006;98(10):1405\u20138.","journal-title":"Am J Cardiol"},{"key":"683_CR12","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532\u201361.","journal-title":"Lancet"},{"issue":"12","key":"683_CR13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/oxfordjournals.aje.a116963","volume":"139","author":"L Kuller","year":"1994","unstructured":"Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O\u2019Leary D, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139(12):1164\u201379.","journal-title":"Am J Epidemiol"},{"key":"683_CR14","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29\u2013e322.","journal-title":"Circulation"},{"issue":"1","key":"683_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1524-6175.2003.02152.x","volume":"5","author":"JM Flack","year":"2003","unstructured":"Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hyperten. 2003;5(1):5\u201311.","journal-title":"J Clin Hyperten"},{"issue":"7","key":"683_CR16","first-page":"955","volume":"177","author":"BH Han","year":"2017","unstructured":"Han BH, Sutin D, Williamston JD, et al. Effect of statin treatment vs usual care in primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA. 2017;177(7):955\u201365.","journal-title":"JAMA"},{"issue":"20","key":"683_CR17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","volume":"135","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Lonn E, Paynter NP, Glynn R, Yusuf S. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135(20):1979\u201381.","journal-title":"Circulation"},{"key":"683_CR18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"683_CR19","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group. Lancet. 1994;344:1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"683_CR20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. NEJM. 1996;335:1001\u20139.","journal-title":"NEJM"},{"key":"683_CR21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","year":"1998","unstructured":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N Engl J Med. 1998;339:1349\u201357.","journal-title":"N Engl J Med"},{"key":"683_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"issue":"1","key":"683_CR23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","volume":"51","author":"J Afilalo","year":"2008","unstructured":"Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. JACC. 2008;51(1):37\u201345.","journal-title":"JACC"},{"issue":"6","key":"683_CR24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248414529622","volume":"19","author":"DH Katz","year":"2014","unstructured":"\u2022 Katz DH, Intwala SS, Stone NJ. Addressing statin adverse effects in the clinic. J Cardiovasc Pharmacol Ther. 2014;19(6):533\u201342. Provides a framework for addressing the most relevant adverse effects of statins in the clinic setting","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"21","key":"683_CR25","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"key":"683_CR26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med. 2005;352:1425\u201335.","journal-title":"New Engl J Med"},{"key":"683_CR27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomized trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"issue":"2","key":"683_CR28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","volume":"238","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329\u201335.","journal-title":"Atherosclerosis"},{"key":"683_CR29","doi-asserted-by":"crossref","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 Randomized Clinical Trial. JAMA 2016;315(15):1580\u20131590.","DOI":"10.1001\/jama.2016.3608"},{"issue":"5","key":"683_CR30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","volume":"160","author":"TR Joy","year":"2014","unstructured":"Joy TR, Monjed A, Zou GY, Hegele RA, McDonald CG, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160(5):301\u201310.","journal-title":"Ann Intern Med"},{"issue":"7","key":"683_CR31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/acm.2013.0216","volume":"20","author":"SA Davis","year":"2014","unstructured":"Davis SA, Feldman SR, Taylor SL. Use of St. John\u2019s Wort in potentially dangerous combinations. J Altern Complement Med. 2014;20(7):578\u20139.","journal-title":"J Altern Complement Med"},{"key":"683_CR32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","volume":"60","author":"MW Russo","year":"2014","unstructured":"Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679\u201386.","journal-title":"Hepatology"},{"issue":"9","key":"683_CR33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2016.05.084","volume":"68","author":"V Fuster","year":"2016","unstructured":"Fuster V, Muntendam P, Mehran R, Baber U, Sartori S, Falk E. A simple disease-guided approach to personalize ACC\/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68(9):881\u201391.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-017-0683-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:12:18Z","timestamp":1750921938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-017-0683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s11883-017-0683-9","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"article-number":"47"}}